肝门部胆管癌隐匿性同时性肝转移的临床特征
该回顾性研究分析了2001至2016年间945例肝门部胆管癌患者,其中672例接受肝切除术,21例(3.1%)经最终病理检出术前和术中未发现的隐匿性肝转移。隐匿性转移灶直径小于显性转移灶(5 mm vs 12 mm,P < .001),且患者生存优于显性转移患者(中位生存17.1 vs 7.4个月,P < .01)。
要点
- 肝门部胆管癌隐匿性肝转移并不罕见,肝切除患者中占3.1%。
- 隐匿性转移灶直径显著小于显性转移灶(5 mm vs 12 mm)。
- 隐匿性转移患者生存优于显性转移患者(17.1 vs 7.4个月)。
核心结论
- 肝门部胆管癌隐匿性肝转移并非极其罕见,细致处理切除标本对检出此类转移至关重要。
- 尽管隐匿性转移患者疾病分期较晚,但其生存优于显性转移患者。
研究设计与样本
- 回顾性队列研究,纳入2001至2016年间治疗的945例肝门部胆管癌患者,其中260例未切除、685例切除(672例肝切除、13例未肝切除)。
主要发现
- 945例中36例有显性肝转移;672例肝切除患者中21例(3.1%)有隐匿性肝转移,中位转移灶数目为1个(范围1-6)。
- 隐匿性转移灶直径小于显性转移灶(5 mm vs 12 mm,P < .001)。
- 与645例无肝转移的肝切除患者相比,21例隐匿性转移患者中微静脉侵犯和淋巴结转移更常见。
- 21例隐匿性转移患者生存优于36例显性转移患者(中位生存时间17.1 vs 7.4个月,P < .01)。
临床怎么用
- 对肝门部胆管癌切除标本应细致处理以检出隐匿性肝转移。
- 隐匿性肝转移患者虽分期较晚,但生存仍优于显性转移患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No authors have reported occult liver metastases from perihilar cholangiocarcinoma (PHCC), which are defined as intrahepatic metastases that are overlooked by preoperative workup and intraoperative inspection but are detected by final pathology. The aim of this study was to clarify the features of such unappreciated metastases. METHODS: We reviewed retrospectively the medical records of patients with PHCC treated between 2001 and 2016 with attention to liver metastases. RESULTS: During the study interval, 945 consecutive patients with PHCC were treated, including 260 unresected and 685 resected patients (672 with hepatectomy and 13 without). Of these, 36 patients had overt liver metastases. Of the 672 hepatectomized patients, 21 (3.1%) patients had occult liver metastases with a median number of 1 (range 1-6). When compared between occult and overt metastases, the diameter was smaller in the former (5 mm vs 12 mm, P < .001). When compared between the 21 patients with occult metastases and the 645 hepatectomized patients without liver metastases, microscopic venous invasion and lymph node metastases were observed frequently in the patients with occult metastases. Survival for these 21 patients with occult metastases was better than that for the 36 patients with overt metastases (median survival time; 17.1 vs 7.4 months, P < .01). CONCLUSION: Occult liver metastases from PHCC are not extremely rare. Meticulous handling of the resected specimens is crucial to detect such metastases. Although patients with occult metastases had advanced stages of the disease, their survival was better than that for patients with overt metastases.
引用
- Ohiwa T, Ebata T, Mizuno T, et al. Occult synchronous liver metastasis from perihilar cholangiocarcinoma. Surgery. 2019. PMID: 31235246. doi:10.1016/j.surg.2019.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。